J&J slides after jury orders it to pay $8 billion in male breast-growth case (JNJ)
Wednesday, 9 October 2019 () · *A Philadelphia jury ruled Johnson & Johnson must pay $8 billion in damages to a man claiming the company didn't properly warn male consumers its Risperdal drug could prompt breast growth.*
· *The company's stock fell as much as 1.5% on Wednesday following the Tuesday decision.*
· *The case, brought by Nicholas Murray, is...
A Philadelphia jury on Tuesday awarded $8 billion in punitive damages against Johnson & Johnson and one if its subsidiaries over a drug the companies made that the plaintiff's attorneys say is linked to the abnormal growth of female breast tissue in boys.
Drugmakers were in the spotlight Wednesday as GSK recalls Zantac after U.S. regulators found probable cancer-causing impurities in the drug. Also in the U.S.: a jury says Johnson & Johnson must pay $8..
Johnson & Johnson (NYSE:JNJ) has been ordered to pay $8 billion in punitive damages to a man who claims the company failed to warn him that antipsychotic drug... Proactive Investors Also reported by •RTTNews •Reuters •Newsmax •Indian Express •NYTimes.com